Ads
related to: when to check psa guidelines- Dosing & Administration
Learn About Dosing Considerations
For This Targeted Treatment.
- Access Information
Find Resources For Your Patients
With Advanced Prostate Cancer.
- Physician Resources
Download The Patient Brochure &
Other Helpful Resources Here.
- Efficacy Information
Physicians, See How A Targeted
Treatment May Help Your Patients.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
The Prostate Health Index (PHI) is a PSA-based blood test for early prostate cancer screening. It may be used to determine when a biopsy is needed. [32] [46] Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44]
In the current recommendation published in 2018, the Task Force recommended that prostate-specific antigen (PSA)-based screening for prostate cancer screenings be an individual decision for men between the ages of 55 and 69. [18] In 2018 the Task Force gave PCa screening a C recommendation. [18]
THE PSA IS a good initial “check engine light” for the prostate, says Garrett Pohlman, M.D., a urologist and host of The Prostate Health Podcast. But it can just tell you that PSA levels are ...
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Richard J. Ablin (May 15, 1940 – October 6, 2023) [1] was an American scientist, most notable for research on prostate cancer.According to the Wall Street Journal: . Richard Ablin, a professor of pathology at University of Arizona College of Medicine, discovered the prostate-specific antigen (PSA) in 1970, and for nearly as long, he has argued that it should not be used for routine screening.